HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Modern HIV treatment offers remarkable outcomes. This guide explores essential first steps, treatment advances, support ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

The National Agency for the Control of AIDS has described information in sections of the media regarding the withdrawal of ...

The PETITE study is evaluating two formulations of dolutegravir in newborn babies under 4 weeks of age – an oral film. In the ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

HIV-positive mothers with undetectable viral load can now safely breastfeed their infants, according to recently updated ...